
Study aims to demystify the immune toxicity triggered by osimertinib-ICI co-treatment
Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide. Epidermal growth factor receptor (EGFR) mutations are common in NSCLC and have made EGFR-targeting drugs like …